{"id":"inactivated-split-virion-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"10-40","effect":"Injection site soreness or erythema"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"1-5","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL6068363","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The split-virion formulation contains disrupted influenza virus particles that present viral antigens to the immune system without causing infection. This triggers both humoral (antibody) and cellular immune responses, enabling the body to mount a rapid defense against subsequent exposure to circulating influenza strains. The inactivated nature ensures safety while maintaining immunogenicity.","oneSentence":"This vaccine stimulates the immune system to recognize and respond to inactivated influenza virus particles, providing protection against seasonal influenza infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:47.316Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT07211152","phase":"PHASE3","title":"Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-10-13","conditions":"Influenza","enrollment":150},{"nctId":"NCT06641180","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-04","conditions":"Influenza","enrollment":1180},{"nctId":"NCT06824519","phase":"PHASE1, PHASE2","title":"Clinical Trials of Quadrivalent Influenza Vaccine","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-05-08","conditions":"Influenza, Human","enrollment":620},{"nctId":"NCT05779020","phase":"PHASE3","title":"Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-04-25","conditions":"Influenza, Human","enrollment":1373},{"nctId":"NCT04137887","phase":"PHASE3","title":"Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-04","conditions":"Influenza (Healthy Volunteers)","enrollment":33096},{"nctId":"NCT06095947","phase":"","title":"Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years","status":"COMPLETED","sponsor":"Hualan Biological Bacterin Co. Ltd.","startDate":"2021-09-15","conditions":"GCP","enrollment":652},{"nctId":"NCT04024228","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-28","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":1539},{"nctId":"NCT06987942","phase":"PHASE4","title":"Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"Varicella, Influenza Vaccine","enrollment":899},{"nctId":"NCT06695117","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-19","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT06059456","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-10-02","conditions":"Influenza Immunization (Healthy Volunteers)","enrollment":2078},{"nctId":"NCT03927131","phase":"PHASE3","title":"Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-05-12","conditions":"Influenza, Human","enrollment":5822},{"nctId":"NCT03755427","phase":"PHASE2","title":"A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-10","conditions":"H7N9 Influenza","enrollment":560},{"nctId":"NCT05895955","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mahidol University","startDate":"2023-11-04","conditions":"Influenza","enrollment":290},{"nctId":"NCT01538940","phase":"PHASE4","title":"Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2011-11-01","conditions":"Influenza","enrollment":415},{"nctId":"NCT05431725","phase":"PHASE3","title":"Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-07-18","conditions":"Seasonal Influenza","enrollment":2202},{"nctId":"NCT05568979","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-06","conditions":"Influenza (Healthy Volunteers)","enrollment":1001},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":"Influenza","enrollment":632},{"nctId":"NCT05642078","phase":"PHASE3","title":"Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-02-18","conditions":"Prevention of Influenza","enrollment":2550},{"nctId":"NCT04363359","phase":"PHASE2","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2020-01-15","conditions":"Influenza","enrollment":1980},{"nctId":"NCT01551823","phase":"PHASE3","title":"The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug）","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2012-03","conditions":"Influenza","enrollment":1200},{"nctId":"NCT01551810","phase":"PHASE3","title":"The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2012-03","conditions":"Influenza","enrollment":1200},{"nctId":"NCT05512494","phase":"PHASE4","title":"Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-11-27","conditions":"Seasonal Influenza","enrollment":1260},{"nctId":"NCT06029933","phase":"","title":"Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years","status":"RECRUITING","sponsor":"Kaiser Permanente","startDate":"2023-08-17","conditions":"Influenza, Community-acquired Pneumonia, Cardiovascular Events","enrollment":960000},{"nctId":"NCT05138705","phase":"PHASE4","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2021-12-14","conditions":"Influenza, Human","enrollment":380},{"nctId":"NCT04695717","phase":"PHASE3","title":"This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-09-05","conditions":"Influenza","enrollment":864},{"nctId":"NCT05832333","phase":"","title":"Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-05","conditions":"Influenza","enrollment":682},{"nctId":"NCT05078060","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-10-12","conditions":"Influenza (Healthy Volunteers)","enrollment":1804},{"nctId":"NCT03930017","phase":"","title":"Pregnancy, Arsenic and Immune Response","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-10-14","conditions":"Arsenic--Toxicology, Immunologic Disorders Complicating Pregnancy, Vaccine Response Impaired","enrollment":784},{"nctId":"NCT03430089","phase":"PHASE1","title":"Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-02-22","conditions":"Influenza, Flu","enrollment":101},{"nctId":"NCT04091880","phase":"PHASE4","title":"Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2019-09-26","conditions":"Enterovirus Infections, Influenza","enrollment":1134},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT05406180","phase":"","title":"Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-10-10","conditions":"Influenza","enrollment":675},{"nctId":"NCT03391193","phase":"PHASE3","title":"Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-12-19","conditions":"Influenza","enrollment":301},{"nctId":"NCT03765437","phase":"PHASE3","title":"Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-01-15","conditions":"Influenza","enrollment":230},{"nctId":"NCT03698279","phase":"PHASE2","title":"Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-09","conditions":"Influenza","enrollment":665},{"nctId":"NCT02550197","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":300},{"nctId":"NCT03300050","phase":"PHASE1","title":"Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2017-10-10","conditions":"Influenza, Vaccine","enrollment":65},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT03390166","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-24","conditions":"Influenza","enrollment":945},{"nctId":"NCT02894840","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-11","conditions":"Influenza","enrollment":340},{"nctId":"NCT01003288","phase":"NA","title":"Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2009-10","conditions":"Healthy","enrollment":255},{"nctId":"NCT03095599","phase":"PHASE2, PHASE3","title":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2017-03-20","conditions":"Influenza, Human","enrollment":889},{"nctId":"NCT02598089","phase":"PHASE1","title":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2015-11","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT02585700","phase":"PHASE1","title":"A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine","status":"COMPLETED","sponsor":"Institute of Virology, Vaccines and Sera, Torlak","startDate":"2015-11","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT01215669","phase":"PHASE4","title":"Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-10","conditions":"Influenza","enrollment":240},{"nctId":"NCT03666806","phase":"PHASE2, PHASE3","title":"Preventing Stroke Triggers in Children With Sickle Cell Anaemia in Mulago Hospital, Kampala (PREST ): a Randomized Control Trial","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2018-08-22","conditions":"Preventing Stroke in Sickle Cell Anaemia","enrollment":150},{"nctId":"NCT01336166","phase":"PHASE2","title":"The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2009-07","conditions":"Influenza","enrollment":480},{"nctId":"NCT01863433","phase":"PHASE4","title":"A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-05","conditions":"Influenza, Human","enrollment":120},{"nctId":"NCT03016143","phase":"PHASE2","title":"Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2016-10","conditions":"Influenza","enrollment":300},{"nctId":"NCT02545543","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2015-09","conditions":"Influenza, Human","enrollment":2278},{"nctId":"NCT00735475","phase":"PHASE4","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-10","conditions":"Influenza","enrollment":1268},{"nctId":"NCT00554333","phase":"PHASE3","title":"Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-10","conditions":"Influenza","enrollment":795},{"nctId":"NCT03057483","phase":"","title":"Active Surveillance for Adverse Events Following Immunization With the Influenza Vaccine Produced at Butantan Institute","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2017-04-06","conditions":"Influenza Vaccines","enrollment":533},{"nctId":"NCT00959049","phase":"PHASE3","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-09","conditions":"Influenza","enrollment":1474},{"nctId":"NCT01665807","phase":"PHASE4","title":"A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine","status":"COMPLETED","sponsor":"Brenda Coleman","startDate":"2012-09","conditions":"Influenza, Vaccination Site Reactions (HT)","enrollment":868},{"nctId":"NCT01680679","phase":"PHASE4","title":"Influenza Immunization of Children in India","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-05","conditions":"Influenza","enrollment":18163},{"nctId":"NCT00644540","phase":"PHASE2","title":"Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-11","conditions":"FLU","enrollment":89},{"nctId":"NCT02710409","phase":"PHASE3","title":"A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2016-01","conditions":"Influenza","enrollment":3664},{"nctId":"NCT00551031","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Influenza, Myxovirus Infection","enrollment":2098},{"nctId":"NCT00743275","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-08","conditions":"Influenza","enrollment":120},{"nctId":"NCT00391053","phase":"PHASE3","title":"Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-10","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":3851},{"nctId":"NCT00524940","phase":"PHASE2","title":"Trial to Describe the Safety and Immunogenicity of Fluzone®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-08","conditions":"Influenza","enrollment":124},{"nctId":"NCT00772109","phase":"PHASE3","title":"Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-10","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":4292},{"nctId":"NCT02723812","phase":"PHASE4","title":"Evaluate Safety of GCFLU® Administered Intramuscularly in Healthy Vietnamese Volunteer Aged From 3 Years Old","status":"COMPLETED","sponsor":"Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products","startDate":"2015-11","conditions":"Influenza, Human","enrollment":120},{"nctId":"NCT01403376","phase":"PHASE2","title":"Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-09","conditions":"Multiple Sclerosis","enrollment":128},{"nctId":"NCT02228980","phase":"PHASE4","title":"Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-09","conditions":"Influenza","enrollment":602},{"nctId":"NCT01967784","phase":"PHASE3","title":"Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-10","conditions":"Influenza","enrollment":100},{"nctId":"NCT02269007","phase":"PHASE1","title":"A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2015-05","conditions":"Influenza","enrollment":110},{"nctId":"NCT01063088","phase":"PHASE3","title":"Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2010-02","conditions":"Influenza","enrollment":211},{"nctId":"NCT01138397","phase":"PHASE3","title":"Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-06","conditions":"Influenza","enrollment":129},{"nctId":"NCT01121822","phase":"PHASE3","title":"Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-05","conditions":"Influenza","enrollment":129},{"nctId":"NCT01032980","phase":"","title":"Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12","conditions":"Influenza, Swine-Origin A/H1N1 Influenza Virus","enrollment":3934},{"nctId":"NCT00776438","phase":"PHASE2","title":"Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Influenza, Orthomyxovirus Infections, Myxovirus Infection","enrollment":160},{"nctId":"NCT01761435","phase":"PHASE3","title":"Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza Vaccination","status":"COMPLETED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-10","conditions":"Infection in Solid Organ Transplant Recipients","enrollment":499},{"nctId":"NCT01368796","phase":"PHASE4","title":"Comparison of 4 Influenza Vaccines in Seniors","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-07","conditions":"Influenza Vaccine","enrollment":953},{"nctId":"NCT02133456","phase":"","title":"A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3 Years and Older","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2014-01","conditions":"Influenza, Vaccination Adverse Event","enrollment":166240},{"nctId":"NCT00718146","phase":"PHASE2","title":"Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-06","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":130},{"nctId":"NCT00343681","phase":"PHASE2","title":"A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":120},{"nctId":"NCT00491257","phase":"PHASE2","title":"A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-06","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":130},{"nctId":"NCT00946179","phase":"PHASE2","title":"Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-05","conditions":"Influenza","enrollment":130},{"nctId":"NCT00954798","phase":"PHASE2","title":"A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-08","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":450},{"nctId":"NCT00491985","phase":"PHASE2","title":"Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-06","conditions":"Influenza, Orthomyxoviridae Infections, Influenza A Virus Infection","enrollment":240},{"nctId":"NCT00383526","phase":"PHASE3","title":"Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":3707},{"nctId":"NCT00884182","phase":"PHASE2","title":"Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-04","conditions":"Influenza, Orthomyxoviridae Infections, Orthomyxovirus Infections","enrollment":350},{"nctId":"NCT01053143","phase":"PHASE3","title":"Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-01","conditions":"Influenza, Pandemic Influenza, Influenza A Virus, H1N1 Subtype","enrollment":100},{"nctId":"NCT01089660","phase":"PHASE2","title":"A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-03","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":202},{"nctId":"NCT00956046","phase":"PHASE2","title":"A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-09","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":401},{"nctId":"NCT00296829","phase":"PHASE2","title":"Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-01","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":1080},{"nctId":"NCT00415129","phase":"PHASE2","title":"Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-06","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":600},{"nctId":"NCT00945438","phase":"PHASE2","title":"Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-05","conditions":"Influenza","enrollment":131},{"nctId":"NCT00545701","phase":"PHASE2","title":"Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-10","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":100},{"nctId":"NCT00956202","phase":"PHASE2","title":"A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-08","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":303},{"nctId":"NCT00383539","phase":"PHASE3","title":"Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":2256},{"nctId":"NCT00606359","phase":"PHASE2","title":"Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-11","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":62},{"nctId":"NCT00457509","phase":"PHASE1","title":"Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-01","conditions":"Pandemic Influenza, Influenza A Virus Infection, Orthomyxoviridae Infections","enrollment":251},{"nctId":"NCT00258934","phase":"PHASE2","title":"Immunogenicity Study of the Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-09","conditions":"Orthomyxoviridae Infections, Influenza","enrollment":978},{"nctId":"NCT00703651","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2003-09","conditions":"Influenza, Orthomyxoviridae Infection, Myxovirus Infection","enrollment":1150},{"nctId":"NCT00775450","phase":"PHASE2","title":"Influenza Vaccine Revaccination in Ambulatory Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-10","conditions":"Influenza, Orthomyxovirus Infection, Myxovirus Infection","enrollment":807},{"nctId":"NCT01481454","phase":"PHASE3","title":"Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-03","conditions":"Influenza","enrollment":1701},{"nctId":"NCT01047202","phase":"PHASE4","title":"Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2009-12","conditions":"Influenza","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vaxigrip"],"phase":"phase_3","status":"active","brandName":"Inactivated Split-virion influenza vaccine","genericName":"Inactivated Split-virion influenza vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to recognize and respond to inactivated influenza virus particles, providing protection against seasonal influenza infection. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}